Abstract 30P
Background
Oral squamous cell carcinoma (OSCC) represents one of the six most common cancers in the world. The identification of new prognostic markers could help clinicians explore the biological characteristics of OSCC and develop more personalized treatment plans for patients based on their risk factors. The discovery and study of new prognostic markers of OSCC may help improve treatment outcomes through more accurate and effective treatment strategies, ultimately leading to improved survival and quality of life in patients with OSCC. The aim of this study was to identify the prognostic value of CDKN2A and miRNAs, involved in its regulation as markers of OSCC.
Methods
In the present study we have results of the examination and treatment of 70 patients with stage II–IV OSCC. miR-10b and -155 and mRNA of CDKN2A in tumor samples of patients with OSCC was analyzed by real-time reverse transcription polymerase chain reaction. Detection of p16INK4a was performed by simultaneous immunohistochemical assessment in tumor cells.
Results
We found a strong correlation of studied miRNAs expression with lymph node metastasis (r=0.56 for miR-10b and 0.59 for miR-155). Also, there is no differences in miR-10b and -155 between p16INK4a+ and p16INK4a- samples. p16INK4a status does not affect the association of both miRNAs with lymph node metastases.
Conclusions
The results indicate the relation between miR-10b and -155 and the presence of lymph node metastases of patients with OSCC and thus they can be used as prognostic markers of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract